Anixa Biosciences (ANIX) said Monday that it received a notice of allowance from the US Patent and Trademark Office for its patent application covering its potential ovarian cancer vaccine.
The patent application includes claims related to methods for eliciting an immune response targeting the anti-Mullerian hormone receptor, type II, or AMHR2, a target for ovarian cancer prevention and treatment, Anixa said.
The allowed claims include methods of administering an immunogenic composition consisting of a nucleic acid encoding the AMHR2 polypeptide, the company said.
Anixa said its ovarian cancer vaccine is being developed in collaboration with the Cleveland Clinic and the National Cancer Institute.
Shares of Anixa were up more than 3% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。